FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3503-3508

  Shan, Jin Lu ^a   Dai, Nan ^a   Yang, Xue Qin ^a   Qian, Cheng Yuan ^a   Yang, Zhen Zhou ^a   Jin, Feng ^a   Li, Mengxia ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; FokI; Meta analysis; Polymorphism; Risk; VDR

Indexed keywords

VITAMIN D RECEPTOR;

ARTICLE; BREAST CANCER; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; EMBASE; FEMALE; FOKI GENE; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; PUBLICATION BIAS; RECEPTORS, CALCITRIOL;

EID: 84898831941     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1462-z     Document Type: Article

References (43)

1. Uitterlinden AG et al. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143-56.
2. Bertone-Johnson ER et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1991-7.
3. Crew KD et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6):598-604.
4. Janowsky EC et al. Association between low levels of 1,25- dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999;2(3):283-91.
5. Lowe LC et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41(8):1164-9.
6. Jensen SS et al. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001;15(8):1370-80.
7. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684-700.
8. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1989;1(8631):188-91.
9. Hansen CM et al. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci. 2001;6:D820-48.
10. Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev. 2003;61(7):227-38.
11. Polly P et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem. 1996;60(3):322-33.
12. Liu M et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10(2):142-53.
13. Polly P et al. 1 alpha,25-dihydroxyvitamin D3 receptor as a mediator of transrepression of retinoid signaling. J Cell Biochem. 1997;67(3):287-96.
14. Berger U et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab. 1988;67(3):607-13.
15. Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1427-37.
16. Barroso E et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer. 2008;8:385.
17. Chen WY et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2335-9.
18. Gapska P et al. Vitamin D receptor variants and breast cancer risk in the polish population. Breast Cancer Res Treat. 2009;115(3):629-33.
19. Sinotte M et al. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. Endocr Relat Cancer. 2008;15(4):975-83.
20. Anderson LN et al. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1708-17.
21. Curran JE et al. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999;83(6):723-6.
22. Guy M et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10(16):5472-81.
23. John EM et al. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol. 2007;166(12):1409-19.
24. Higgins JP et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
27. Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
28. McCullough ML et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007;9(1):R9.
29. Abbas S et al. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res. 2008;10(2):R31.
30. McKay JD et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(1):297-305.
31. Engel LS et al. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1856-67.
32. Rollison DE et al. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S.A. Breast Cancer Res Treat. 2012;132(2):683-91.
33. Fuhrman BJ et al. Sunlight, polymorphisms of vitamin D-related genes and risk of breast cancer. Anticancer Res. 2013;33(2):543-51.
34. Mishra DK et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One. 2013;8(3):e57967.
35. Shahbazi S et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.
36. Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs - a brief overview. Mol Cell Biochem. 2003;253(1-2):247-54.
37. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(6 Suppl):1721S-4S.
38. Bouillon R et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726-76.
39. Arai H et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res. 1997;12(6):915-21.
40. Raimondi S et al. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170-80.
41. Tang C et al. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;117(2):391-9.
42. Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120(1):211-6.
43. Thakkinstian A et al. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291-306.